CTOs on the Move


 
OpGen, Inc. is a leading innovator in rapid, accurate genomic and DNA analysis systems and services.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.opgen.com
  • 708 Quince Orchard Rd Ste 160
    Gaithersburg, MD USA 20878
  • Phone: 301.869.9683

Executives

Name Title Contact Details

Similar Companies

Clear Cycle

Clear Cycle is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SK pharmteco

Headquartered in Rancho Cordova, California, SK pharmteco is a global contract development and manufacturing organization specializing in the production of active pharmaceutical ingredients (APIs), advanced intermediates, and cell and gene therapy for the pharmaceutical industry. Built on 80 years of experience, our global operations have the capability and capacity to support client needs from development through commercial production. SK pharmteco is owned by SK Inc., the strategic investment arm of South Koreas SK Group.

Paige.AI

PAIGE is being built by a dedicated team of Machine Learning experts and pathologists from the leading cancer center in the US and experienced business leadership.

Michigan Medicine

Michigan Medicine, based in Ann Arbor, Michigan, is part of one of the world`s leading universities. Michigan Medicine is a premier, highly ranked academic medical center and award-winning health care system with state-of-the-art facilities. Our vision is to create the future of health care through scientific discovery, innovations in education, and the most effective and compassionate care.

Lumos Pharma

Lumos Pharma, based in Austin, Texas, is an early stage biotechnology company created to develop and commercialize a novel treatment for the rare disease Creatine Transporter Deficiency. Lumos Pharma is the exclusive licensee of technology and discoveries made in laboratories at the University of Cincinnati and has partnered with Key Opinion Leaders in the field and the United States National Institutes of Health to ensure success in developing a treatment for Creatine Transporter Deficiency.